Visão geral da empresa
A clinical-stage biopharmaceutical enterprise, ImageneBio, Inc. focuses on developing therapeutic agents designed to treat patients suffering from immunological, autoimmune, and inflammatory diseases. The company operates within the Healthcare sector, specifically the Biotechnology industry, a classification that signifies an early-stage development phase characterized by high research intensity and significant capital requirements before commercial product launch. ImageneBio, Inc. currently holds a market capitalization of $53.13M and reports a trailing twelve-month revenue of $800,000, supported by a workforce of 15 employees. These financial metrics indicate that the company maintains a relatively small market presence with limited annual sales, which is typical for biotechnology firms that have not yet achieved widespread commercialization of their lead product candidates.
Saúde financeira
The company reported a revenue of $800,000 and a net income of $-52,395,000 over the trailing twelve-month period, while EBITDA stood at $-48,052,000. The substantial gap between the minimal revenue figure and the significant negative net income reveals a cost structure dominated by research and development expenses rather than cost of goods sold, which is inherent to the biotechnology sector's pre-revenue stage. Free cash flow is reported at $-18,874,876, indicating that the company is burning cash to fund its operations and development pipeline, thereby limiting immediate financial flexibility without external capital injections. Despite the negative operating margin of -6056.4% and a profit margin of 0.0%, the company maintains a gross margin of 100.0%, suggesting that revenue generation incurs no direct production costs prior to sales realization. The balance sheet shows a cash position of $135.35M against total debt of $2.98M, resulting in a debt-to-equity ratio of 2.23. Although the company holds substantial liquidity, the elevated debt-to-equity ratio suggests a leveraged capital structure relative to its equity base, yet the absolute debt amount remains low compared to available cash reserves. The current ratio is calculated at 12.49, which indicates a highly conservative stance regarding short-term liquidity and the ability to meet immediate obligations with current assets. Return on Equity stands at -68.9% and Return on Assets at -35.9%, metrics that reveal management is currently utilizing the company's equity and assets to generate losses rather than profits, reflecting the inherent risks of clinical-stage development.
Avaliação de valorização
The trailing twelve-month P/E ratio is N/A due to negative earnings, while the forward P/E is listed as -1.41, a metric that implies the market is pricing in future profitability expectations despite current losses. The price-to-book ratio is 0.40, indicating that the market values the company's equity at 40% of its book value, which often suggests a deep discount for speculative assets with high uncertainty regarding future commercial success. Alternative valuation metrics include a price-to-sales ratio of 66.41 and an EV/EBITDA of 1.65, figures that suggest the market is placing a high premium on the company's potential and intellectual property rather than current earnings power. The 52-week trading range spans from a low of $3.94 to a high of $18.00, providing a historical context for price volatility within the current fiscal year. Based on the available data points, the specific current trading price relative to the 52-week high and low cannot be mathematically determined without the real-time share price input, though the range itself defines the maximum historical fluctuation observed in the last year. The beta value is listed as N/A, meaning that standard statistical volatility relative to the broader market index cannot be calculated with the provided information, leaving the assessment of systematic risk incomplete based strictly on these metrics.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, preventing a direct comparison of growth rates between the two metrics at this specific point in time. ImageneBio, Inc. does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. Consequently, the company does not distribute cash to shareholders, as it must reinvest all available earnings and capital proceeds into research, development, and operational expansion to sustain its clinical pipeline. Since the company currently generates losses and does not pay dividends, the income profile is entirely dependent on potential future appreciation of equity value rather than yield. The overall growth and income profile is characterized by a lack of historical growth data and a complete absence of dividend income, relying instead on the capital appreciation potential of a speculative biotechnology asset.